The Effect of Treatment for Colorectal Cancer on Long-Term Health-Related Quality of Life
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Background: Little information is available on the impact that therapies used in the treatment of colorectal cancer (CRC) have on long-term, health-related quality of life (HRQL). Knowledge of how HRQL is affected by these therapies is essential in properly selecting patients for treatment. The purpose of this study was to determine the long-term impact that surgical and adjuvant therapy for resectable CRC has on patient-reported HRQL in a male veteran population through a case-control design.
Methods: All participating patients had completed therapy at least 6 months before enrollment. One hundred fifty-eight patients were accrued over a 3-year period (January 1, 1997 to December 31, 1999) at a single institution. The impact of CRC surgery on HRQL was measured by comparing a cohort of 61 patients undergoing surgery alone for the treatment of CRC (CRC-S group) with 44 patients undergoing surgery for benign colonic disease (BCD group). To study the effect of adjuvant therapy for CRC on HRQL, a third cohort of 53 patients undergoing both surgical and adjuvant treatment (CRC-S/A group) was compared with the CRC-S group. For each group, health status was measured by a health survey questionnaire, SHORT FORM 36 (SF36). For patients treated for CRC, an additional disease-specific supplemental questionnaire also was used.
Results: Self-reported health status, as measured by mean SF36 score, was significantly reduced for the BCD group compared with CRC-S patients on general health perception (41.9 ± 3.9 vs. 52.2 ± 3.0, P = .04) and the standardized physical component score (31.2 ± 1.7 vs. 37.5 ± 1.5, P < .005). Despite an increased number of distally located tumors, later stage cancers, and an increased number of recurrences in the CRC-S/A group compared with the CRC-S cohort, no significant differences were identified between these groups on any of the subscales or standardized scores of SF36. Using the supplemental questions, no differences were identified between the CRC groups with respect to appetite, weight, or gastrointestinal or urinary functioning.
Conclusions: Surgical therapy for CRC probably has minimal impact on long-term HRQL when compared with surgery for benign colonic processes. Similarly, there does not appear to be a measurable, lasting impact of CRC adjuvant therapy on HRQL when compared with surgery alone. Although overall impact of therapies for CRC on HRQL appears to be limited, measurement of therapeutic influence on an individual level and identification of selection criteria based on estimated impact on HRQL for these therapies requires prospective validation.
- Ooi BS, Tjandra JJ, Green MD. Morbidities of adjuvant chemotherapy and radiotherapy for resectable rectal cancer. Dis Colon Rectum 1999; 42: 403–18.
- Camilleri-Brennan J, Steele RJC. Quality of life after treatment for rectal cancer. Br J Surg 1998; 85: 1036–43.
- DeCosse JJ, Cennerazzo WJ. Quality of life management of patients with colorectal cancer. CA Cancer J Clin 1997; 47: 198–206.
- Sprangers MA, Taal BG, Aaronson NK, te Velde A. Quality of life in colorectal cancer: stoma vs. nonstoma patients. Dis Colon Rectum 1995; 38: 361–9.
- Balslev I, Harding H. Sexual dysfunction following operation for carcinoma of the rectum. Dis Colon Rectum 1983; 26: 785–8.
- Kuchenhoff J, Wirsching M, Druner HU, Hermann G, Kohler C. Coping with a stoma—a comparative study of patients with rectal carcinoma or inflammatory bowel diseases. Psychother Psychosom 1981; 36: 98–104. CrossRef
- Gelber RD, Goldhirsch A, Cole BF, Wieand HS, Schroeder G, Krook JE. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst 1996; 88: 1039–45.
- Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). Med Care 1992; 30: 473–83.
- Ware JE. Scoring the SF-36. In: Ware JE, ed. SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center, 1993: 1–22.
- Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for the adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352–8. CrossRef
- Anonymous. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939–44.
- Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989; 7: 1447–56.
- Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324: 709–15. CrossRef
- Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Nat Cancer Inst 1988; 80: 21–9.
- Siegrist J, Junge A. Conceptual and methodological problems in research on the quality of life in clinical medicine. Soc Sci Med 1989; 29: 463–8.
- Bernhard J, Hurny C, Mailbach R, Herrmann R, Laffer U. Quality of life as subjective experience: reframing of perception in patients with colon cancer undergoing radical resection with or without chemotherapy. Ann Oncol 1999; 10: 775–82.
- Zaniboni A, Labianca R, Marsoni S, et al. GIVIO-SITAC-01: a randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma-long term results and evaluation of the indicators of health-related quality of life. Cancer 1998; 82: 2135–44.
- The Effect of Treatment for Colorectal Cancer on Long-Term Health-Related Quality of Life
Annals of Surgical Oncology
Volume 8, Issue 1 , pp 44-49
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Colorectal cancer
- Health-related quality of life
- Industry Sectors
- Author Affiliations
- 1. Department of Surgery, The University of Texas Southwestern Medical Center and the Veterans Affairs North Texas Health Care System, Dallas, Texas
- 4. Assistant Professor of Surgery,, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75235-9161
- 2. Department of Radiation Therapy, The University of Texas Southwestern Medical Center and the Veterans Affairs North Texas Health Care System, Dallas, Texas
- 3. Department of Hematology-Oncology, The University of Texas Southwestern Medical Center and the Veterans Affairs North Texas Health Care System, Dallas, Texas